Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves in-depth molecular simulations of the ion channel in its native membrane environment, including its open, closed, and inactivated states, along with ensemble virtual screening that focuses on conformational mobility for each state. Tentative binding pockets are identified inside the pore, in the gating area, and at allosteric sites to address every conceivable mechanism of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96PR1

UPID:
KCNC2_HUMAN

ALTERNATIVE NAMES:
Shaw-like potassium channel; Voltage-gated potassium channel Kv3.2

ALTERNATIVE UPACC:
Q96PR1; B7Z231; F5H030; J3KPP5; Q4LE77; Q86W09; Q8N1V9; Q96PR0

BACKGROUND:
Kv3.2, known for its alternative names Shaw-like potassium channel and Voltage-gated potassium channel Kv3.2, is essential for maintaining the fidelity of synaptic transmission in GABAergic interneurons by ensuring action potential repolarization. Its function is vital for the long-range synchronization of gamma oscillations in the neocortex, contributing to the complex processes of learning, memory, and behavior.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Kv3.2 could open doors to potential therapeutic strategies. Given its involvement in Developmental and epileptic encephalopathy 103, a disorder characterized by early-onset epilepsies and cognitive impairment, Kv3.2 emerges as a promising target for developing novel treatments aimed at improving neurological outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.